Cargando…

Response to: Ruxolitinib withdrawal due to the COVID-19

Detalles Bibliográficos
Autores principales:	Barbui, Tiziano, Carobbio, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905976/ https://www.ncbi.nlm.nih.gov/pubmed/33633312 http://dx.doi.org/10.1038/s41375-021-01187-4

Ejemplares similares

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
por: Ghirardi, Arianna, et al.
Publicado: (2018)

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
por: Li, Hailan, et al.
Publicado: (2020)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

Ruxolitinib withdrawal complicating emergency aortic root replacement
por: Szpytma, Malgorzata (Maggie), et al.
Publicado: (2022)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
por: Harrington, Patrick, et al.
Publicado: (2022)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib
por: Song, Yue, et al.
Publicado: (2022)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2020)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis
por: Meng, Guang-Qiang, et al.
Publicado: (2021)

Benfluorex withdrawal in France: Still be hiding somewhere in the world?
por: Frachon, Irène, et al.
Publicado: (2011)

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018)

Long-term follow-up of recovered MPN patients with COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Immune thrombocytopenia due to COVID‐19 during pregnancy
por: Tang, M.W., et al.
Publicado: (2020)

Response to: Nutritional strategies for the rehabilitation of COVID-19 patients
por: Brugliera, Luigia, et al.
Publicado: (2020)

Second versus first wave of COVID-19 in patients with MPN
por: Barbui, Tiziano, et al.
Publicado: (2022)

Disparities in the recovery from critical illness due to COVID-19
por: Johnson, Shawn F, et al.
Publicado: (2020)

The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Coagulation Abnormalities Due to COVID-19 in a Child with Thalassemia: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Reduction in air pollution and attributable mortality due to COVID-19 lockdown
por: Achebak, Hicham, et al.
Publicado: (2020)

Ancient Disease Making a Comeback Due to Covid-19 Pandemic
por: Gupta, Sanjeev, et al.
Publicado: (2022)

Screening pediatric delirium with an adapted version of the Sophia Observation withdrawal Symptoms scale (SOS)
por: van Dijk, Monique, et al.
Publicado: (2011)

Xenophobia due to the coronavirus outbreak – A letter to the editor in response to “the socio-economic implications of the coronavirus pandemic (COVID-19): A review”
por: Cheng, Shuliang Oliver
Publicado: (2020)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Pulmonary Vascular Changes in Acute Respiratory Distress Syndrome due to COVID-19
por: Jha, Ajay Kumar
Publicado: (2021)

Coagulation Abnormalities Due to COVID-19 in a Child with Thalassemia: Authors’ Reply
por: Marhaeni, Wulandewi, et al.
Publicado: (2021)

Have deaths from COVID-19 in Europe plateaued due to herd immunity?
por: Okell, Lucy C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7p8dhlpvvg1mn8jla71s4uca6j